Argo Biopharmaceutical Co. Ltd. and its RNAi work drew Novartis AG back to the table for a third time, as the companies entered a potential $5.2 billion deal involving cardiovascular-focused assets, including a right to first negotiation for BW-00112, an angiopoietin-like protein 3-targeting siRNA in phase II testing in severe hypertriglyceridemia. Read More
Oddsmakers placing their bets on which drugs will be in play for round 3 of the U.S. Inflation Reduction Act (IRA) price negotiations are doing some reshuffling, thanks to an orphan drug provision tucked into the Trump administration’s One Big Beautiful Bill Act (OBBBA) that was signed into law on the Fourth of July. Read More
As Wave Life Sciences Ltd. released more results from its ongoing phase Ib/IIa study of small interfering RNA editing oligonucleotide WVE-006 for treating alpha-1 antitrypsin deficiency, the company’s stock (NASDAQ:WVE) dropped by 16.8% to close at $8 on Sept. 3. Read More
The vaccine dominoes continue to fall in the U.S. This time one fell on the FDA’s Vaccines and Related Biological Products Advisory Committee, as one of Health and Human Services Secretary Robert Kennedy’s most outspoken critics was removed from the panel nearly a year and a half before his term was to expire. Read More
Argenica Therapeutics Ltd. saw its stock drop 56% following mixed results for its ARG-007 phase II Seancon trial in acute ischemic stroke patients undergoing endovascular revascularization, or thrombectomy. Read More
There have been numerous improvements in the treatment of cardiovascular disease since the European Society of Cardiology (ESC) first met in 1950, but unmet medical need remains and the science continues to advance, as delegates heard at the 75th annual meeting in Madrid, Spain, Aug. 29-Sept. 1. Read More
Several South Korean biotech and biopharmaceutical companies completed IND submissions or won nods to start clinical trials in either the U.S. or South Korea, including SK Bioscience Co. Ltd., Genosco Inc., Pimedbio Inc., Sillajen Inc. and Ami Pharm Co. Ltd.
Bioxcel Therapeutics Inc.’s phase III results in bipolar disorders or schizophrenia could bring Igalmi out of the clinic and into patients' homes for easier treatment. Vimal Mehta, Bioxcel CEO, talks about the potential with BioWorld's Lee Landenberger. Read More
New hires and promotions in the biopharma industry, including: 4D, Aera, Candel, Cormedix, Cybin, Exelixis, Hemab, Kala, Maze, Melodia, Merck KGaA, Neurotech, Opus, Pharming, Trimtech, Vor. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: Astrazeneca, Cormedix, Eli Lilly, Enveric, Fibrogen, Genentech, Ideaya, Medicus, Melinta, MS Pharma, Novartis, Novo Nordisk, Olema, Omass, Omeros, Pfizer, Polaritybio, Polypharma, Roche, Scholar Rock, Servier. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Bioarctic, Boehringer, Eisai, Encoded, Henlius, Menarini, Nanoscope, Organon, Sanofi, Shionogi, Zai Lab. Read More
